A Comparison between Placental and Amniotic Mesenchymal Stem Cells in Transamniotic Stem Cell Therapy for Experimental Gastroschisis
jpedsurg.org shows its articles on its own site.
Read the article on jpedsurg.org ↗Article · Nov 2019 · 1 min read
In brief
In brief
This experimental study compares placental versus amniotic fluid-derived mesenchymal stem cells for treating gastroschisis via intraamniotic injection in a rat model. Researchers evaluated intestinal wall thickness outcomes to determine which stem cell source shows greater therapeutic potential for this congenital abdominal wall defect.
Written by the GCMD Library team from the article.
Purpose
We compared placental and amniotic fluid-derived mesenchymal stem cells (pMSCs and afMSCs, respectively) in transamniotic stem cell therapy for experimental gastroschisis.
Methods
Gastroschisis was surgically created in 126 rat fetuses at gestational day 18 (term = 22 days), immediately followed by volume-matched intraamniotic injections of suspensions of afMSCs (n = 32), pMSCs (n = 33), or normal saline (NS) (n = 33). Untreated fetuses served as controls (n = 28). Blinded observers performed computerized measurements of total and segmental (serosa, muscularis, and mucosa) intestinal wall thickness on the herniated bowel at term. Statistical analysis included ANOVA, the Wald test, and Levene's test (p